Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections?

Published

Journal Article

For more than 4 decades, vancomycin has been the antibiotic of choice for methicillin-resistant Staphylococcus aureus (MRSA) infections. Recently, infections due to isolates with high but susceptible vancomycin minimum inhibitory concentrations have been associated with additional treatment failures and patient mortality. These poorer outcomes may in part be explained by the inability of attaining appropriate vancomycin levels in these patients. However, assumptions that these poor outcomes are solely due to failure to achieve optimal serum levels of vancomycin are premature. The availability of effective alternatives further erodes the position of vancomycin as first-line therapy. The emergence of resistance and cost considerations, however, favor a more measured approach when using alternative antimicrobials. Collectively, the current available data suggest that the optimal therapy for MRSA infections remains unclear. In the absence of further data, the Infectious Diseases Society of America guidelines remain relevant and inform clinicians of best practice for treating patients with MRSA infections.

Full Text

Duke Authors

Cited Authors

  • van Hal, SJ; Fowler, VG

Published Date

  • June 2013

Published In

Volume / Issue

  • 56 / 12

Start / End Page

  • 1779 - 1788

PubMed ID

  • 23511300

Pubmed Central ID

  • 23511300

Electronic International Standard Serial Number (EISSN)

  • 1537-6591

Digital Object Identifier (DOI)

  • 10.1093/cid/cit178

Language

  • eng

Conference Location

  • United States